GERMANTOWN, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced poster presentations at two upcoming scientific conferences. Presentations include preclinical data in both of the company's stem cell and small molecule platforms at the Society for Neurosciences Annual Meeting, as well as the American College of Toxicology Annual Meeting. Following is a schedule of relevant presentations: 2016 American College of Toxicology Annual Meeting Title: "Comprehensive In Vivo Nonclinical Safety Assessment of NSI-189, a Small Molecule New Chemical Entity for the Treatment of Major Depressive Disorder" Date: Monday, November 7 Time: 5:30-7 PM EST Presenter: Grace Furman, PhD, CEO Paracelsus, Inc Location: Baltimore Marriott Waterfront, Baltimore, MD 2016 Society for Neurosciences Annual MeetingTitle: "NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57BL/6 mice and reverses LTP impairment in a mouse model of Angelman Syndrome" Date: Sunday, November 13 Time: 1-5 PM PT Presenter: Michel Baudry, PhD, Graduate College of Biomedical Sciences, Western University of Health Location: San Diego Convention Center (San Diego, CA) Title: "Durable engraftment, neuronal differentiation of human fetal neural stem cell transplants in penetrating ballistic-like brain injury accompanied by amelioration of cognitive deficits." Date: Monday, November 14 Time: 8AM-12PM PT Presenter: Shyam Gajavelli, PhD, University of Miami Location: San Diego Convention Center (San Diego, CA) Title: "Induction of immune tolerance by short-course immunosuppression after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury" Date: Monday, November 14 Time: 8AM-12PM PT Presenter: Martin Marsala, MD, University of San Diego School of Medicine Location: San Diego Convention Center (San Diego, CA) Title: "Remyelinating human oligodendrocyte progenitors for regenerative treatment of demyelinating diseases and spinal cord injury" Date: Wed, November 16 Time: 8AM-12PM PT Presenter: Tom Hazel, PhD, VP of Research, Neuralstem, Inc. Location: San Diego Convention Center (San Diego, CA) About Neuralstem Neuralstem's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential therapies for multiple central nervous system diseases and conditions.